KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Edwards Lifesciences (EW) Equity Average (2016 - 2025)

Historic Equity Average for Edwards Lifesciences (EW) over the last 16 years, with Q3 2025 value amounting to $10.4 billion.

  • Edwards Lifesciences' Equity Average rose 2159.09% to $10.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 billion, marking a year-over-year increase of 2159.09%. This contributed to the annual value of $8.4 billion for FY2024, which is 3397.87% up from last year.
  • Edwards Lifesciences' Equity Average amounted to $10.4 billion in Q3 2025, which was up 2159.09% from $10.4 billion recorded in Q2 2025.
  • In the past 5 years, Edwards Lifesciences' Equity Average registered a high of $10.4 billion during Q3 2025, and its lowest value of $4.6 billion during Q1 2021.
  • Moreover, its 5-year median value for Equity Average was $6.3 billion (2023), whereas its average is $7.0 billion.
  • In the last 5 years, Edwards Lifesciences' Equity Average skyrocketed by 160.86% in 2023 and then soared by 4631.54% in 2024.
  • Edwards Lifesciences' Equity Average (Quarter) stood at $5.7 billion in 2021, then grew by 5.69% to $6.0 billion in 2022, then grew by 11.83% to $6.7 billion in 2023, then surged by 46.32% to $9.8 billion in 2024, then grew by 5.78% to $10.4 billion in 2025.
  • Its last three reported values are $10.4 billion in Q3 2025, $10.4 billion for Q2 2025, and $10.1 billion during Q1 2025.